Background and Purpose—To estimate the cost-effectiveness of stroke prevention in
patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg …

Objective To compare the efficacy, safety, and cost effectiveness of direct acting oral
anticoagulants (DOACs) for patients with atrial fibrillation. Design Systematic review …

Background: Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF)
imposes a substantial economic burden on the UK healthcare system. Objectives: An …

The concept of net clinical benefit has been used to quantify the balance between risk of
ischaemic stroke (IS) and risk of intracranial haemorrhage (ICH) with the use oral …

Background Vitamin K antagonists, such as warfarin, are standard treatments for stroke
prophylaxis in patients with atrial fibrillation. Patient outcomes depend on quality of warfarin …

Atrial fibrillation (AF) is a common arrhythmia and the leading cause of stroke, an event with
high human and economic burden. Novel oral anticoagulants have been approved in many …

Objective Three oral anticoagulants have reported study results for stroke prevention in
patients with atrial fibrillation (AF)(dabigatran etexilate, rivaroxaban and apixaban); all …

Aim Anticoagulant prophylaxis with vitamin K antagonists (such as warfarin) is effective in
reducing the risk of stroke in patients with atrial fibrillation (AF). New oral anticoagulants …

Abstract Introduction The Apixaban for the Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE), Randomized Evaluation of Long-term …

In the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation
(ARISTOTLE) trial, apixaban is comparable to a vitamin K antagonist (VKA) in reducing …